{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:03:39Z","timestamp":1788951819708,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s13555-016-0106-9","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T14:33:34Z","timestamp":1458311614000},"page":"237-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis"],"prefix":"10.1007","volume":"6","author":[{"given":"Anthony","family":"Bewley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Sch\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Kerrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,16]]},"reference":[{"issue":"4","key":"106_CR1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"106_CR2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","volume":"163","author":"B Aksoy","year":"2010","unstructured":"Aksoy B, Altaykan-Hapa A, Egemen D, Karag\u00f6z F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163(4):719\u201325.","journal-title":"Br J Dermatol"},{"key":"106_CR3","unstructured":"National rosacea Society survey available at: http:\/\/www.rosacea.org\/weblog\/survey-shows-facial-redness-takes-emotional-toll . Accessed Jan 28, 2016."},{"issue":"6","key":"106_CR4","first-page":"522","volume":"17","author":"NJ Lowe","year":"1991","unstructured":"Lowe NJ, Behr KL, Fitzpatrick R, Goldman M, Ruiz-Esparza J. Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol. 1991;17(6):522\u20135.","journal-title":"J Dermatol Surg Oncol."},{"issue":"3","key":"106_CR5","first-page":"181","volume":"75","author":"R Balkrishnan","year":"2005","unstructured":"Balkrishnan R, McMichael AJ, Hu JY, et al. Corrective cosmetics are effective for women with facial pigmentary disorders. Cutis. 2005;75(3):181\u20137.","journal-title":"Cutis"},{"key":"106_CR6","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:CD003262.","DOI":"10.1002\/14651858.CD003262.pub5"},{"issue":"4","key":"106_CR7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-1976","volume":"95","author":"MM Linden van der","year":"2015","unstructured":"van der Linden MM, van Rappard DC, Daams JG, Sprangers MA, Spuls PI, de Korte J. Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol. 2015;95(4):395\u2013400.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"106_CR8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jaad.2009.08.020","volume":"62","author":"SP Kini","year":"2010","unstructured":"Kini SP, Nicholson K, De Long LK, et al. A pilot study in discrepancies in quality of life among three cutaneous types of rosacea. J Am Acad Dermatol. 2010;62(6):1069\u201371.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"106_CR9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14764170902741311","volume":"11","author":"N Menezes","year":"2009","unstructured":"Menezes N, Moreira A, Mota G, Baptista A. Quality of life and rosacea: pulsed dye laser impact. J Cosmet Laser Ther. 2009;11(3):139\u201341.","journal-title":"J Cosmet Laser Ther."},{"issue":"4","key":"106_CR10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2004.04.010","volume":"51","author":"SR Tan","year":"2004","unstructured":"Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol. 2004;51(4):592\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"106_CR11","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/jdv.13305","volume":"29","author":"AM Layton","year":"2015","unstructured":"Layton AM, Schaller M, Homey B, et al. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomised double-blind vehicle-controlled study. J Eur Acad Dermatol Venereol. 2015;29:2405\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"106_CR12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","volume":"166","author":"J Fowler","year":"2012","unstructured":"Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633\u201341.","journal-title":"Br J Dermatol"},{"key":"106_CR13","first-page":"650","volume":"12","author":"J Fowler Jr","year":"2013","unstructured":"Fowler J Jr, Jackson JM, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12:650\u20136.","journal-title":"J Drugs Dermatol"},{"key":"106_CR14","first-page":"56","volume":"13","author":"A Moore","year":"2014","unstructured":"Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13:56\u201361.","journal-title":"J Drugs Dermatol"},{"key":"106_CR15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jdv.13556","volume":"30","author":"J Tan","year":"2016","unstructured":"Tan J, Sch\u00f6fer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M, The RISE study group. Prevalence of rosacea in the general population of Germany and Russia\u2014the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"106_CR16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"106_CR17","first-page":"167","volume":"6","author":"AH M\u00f8ller","year":"2015","unstructured":"M\u00f8ller AH, Erntoft S, Vinding GR, Jemec GB. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 2015;6:167\u201377.","journal-title":"Patient Relat Outcome Meas."},{"key":"106_CR18","doi-asserted-by":"crossref","unstructured":"Lewis V, Finlay AY. 10\u00a0Years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169\u201380 (Review).","DOI":"10.1111\/j.1087-0024.2004.09113.x"},{"issue":"2","key":"106_CR19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13555-015-0077-2","volume":"5","author":"T Dirschka","year":"2015","unstructured":"Dirschka T, Micali G, Papadopoulos L, Tan J, Layton A, Moore S. Perceptions on the psychological impact of facial erythema associated with Rosacea: results of International Survey. Dermatol Ther (Heidelb). 2015;5(2):117\u201327.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"106_CR20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/jdv.12587","volume":"29","author":"J Fowler","year":"2015","unstructured":"Fowler J, Tan J, Jackson JM, et al. Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema. J Eur Acad Dermatol Venereol. 2015;29:474\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"106_CR21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13555-015-0078-1","volume":"5","author":"AW Johnson","year":"2015","unstructured":"Johnson AW, Johnson SM. The role of topical brimonidine tartrate gel as a novel therapeutic option for persistent facial erythema associated with rosacea. Dermatol Ther (Heidelb). 2015;5(3):171\u201381.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"5","key":"106_CR22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaad.2014.05.036","volume":"71","author":"F Moustafa","year":"2014","unstructured":"Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014;71(5):973\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"106_CR23","first-page":"348","volume":"6","author":"TT Huynh","year":"2013","unstructured":"Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life. Am Health Drug Benefits. 2013;6(6):348\u201354.","journal-title":"Am Health Drug Benefits."},{"issue":"S1","key":"106_CR24","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.2310\/7750.2006.00073","volume":"11","author":"J Tan","year":"2007","unstructured":"Tan J. Challenges and solutions in selecting systemic antipsoriasis agents. J Cutan Med Surg. 2007;11(S1):S48\u201353.","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"106_CR25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107619","volume":"215","author":"L Naldi","year":"2007","unstructured":"Naldi L. Health-related quality of life: from health economics to bedside? Dermatology. 2007;215(4):273\u20136.","journal-title":"Dermatology"},{"issue":"2","key":"106_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.det.2011.12.001","volume":"30","author":"SC Chen","year":"2012","unstructured":"Chen SC. Health-related quality of life in dermatology: introduction and overview. Dermatol Clin. 2012;30(2):205\u20138.","journal-title":"Dermatol Clin"},{"issue":"7297","key":"106_CR27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.322.7297.1297","volume":"322","author":"IJ Higginson","year":"2001","unstructured":"Higginson IJ, Carr AJ. Measuring quality of life: using quality of life measures in the clinical setting. BMJ. 2001;322(7297):1297\u2013300.","journal-title":"BMJ"},{"issue":"4","key":"106_CR28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000107625","volume":"215","author":"S Salek","year":"2007","unstructured":"Salek S, Roberts A, Finlay AY. The practical reality of using a patient-reported outcome measure in a routine dermatology clinic. Dermatology. 2007;215(4):315\u20139.","journal-title":"Dermatology"}],"updated-by":[{"DOI":"10.1007\/s13555-016-0111-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-016-0106-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:36:39Z","timestamp":1498278999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-016-0106-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,16]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["106"],"URL":"https:\/\/doi.org\/10.1007\/s13555-016-0106-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726237961.793552700","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,16]]}}}